- Home
- CTSO vs VRCA Comparison
CTSO vs VRCA Comparison
Compare CTSO & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- VRCA
- Stock Information
- Founded
- CTSO 1997
- VRCA 2013
- Country
- CTSO United States
- VRCA United States
- Employees
- CTSO N/A
- VRCA N/A
- Industry
- CTSO Medical/Dental Instruments
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- CTSO Health Care
- VRCA Health Care
- Exchange
- CTSO Nasdaq
- VRCA Nasdaq
- Market Cap
- CTSO 51.6M
- VRCA 58.0M
- IPO Year
- CTSO N/A
- VRCA 2018
- Fundamental
- Price
- CTSO $1.08
- VRCA $0.58
- Analyst Decision
- CTSO Strong Buy
- VRCA Hold
- Analyst Count
- CTSO 3
- VRCA 5
- Target Price
- CTSO $4.67
- VRCA $6.00
- AVG Volume (30 Days)
- CTSO 159.7K
- VRCA 312.6K
- Earning Date
- CTSO 05-08-2025
- VRCA 03-11-2025
- Dividend Yield
- CTSO N/A
- VRCA N/A
- EPS Growth
- CTSO N/A
- VRCA N/A
- EPS
- CTSO N/A
- VRCA N/A
- Revenue
- CTSO $37,739,531.00
- VRCA $7,566,000.00
- Revenue This Year
- CTSO $9.20
- VRCA $93.38
- Revenue Next Year
- CTSO $11.64
- VRCA $127.27
- P/E Ratio
- CTSO N/A
- VRCA N/A
- Revenue Growth
- CTSO 1.80
- VRCA 47.66
- 52 Week Low
- CTSO $0.70
- VRCA $0.54
- 52 Week High
- CTSO $1.61
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- CTSO 45.16
- VRCA 40.24
- Support Level
- CTSO $0.99
- VRCA $0.58
- Resistance Level
- CTSO $1.15
- VRCA $0.68
- Average True Range (ATR)
- CTSO 0.08
- VRCA 0.07
- MACD
- CTSO -0.02
- VRCA -0.00
- Stochastic Oscillator
- CTSO 10.53
- VRCA 24.77
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.